Cardioprotective Mechanism of Shenshao Capsule Against Myocardial Ischemia-reperfusion Injury in Rats Based on NF-B Pathway

ZHAO Gui-feng; HUANG Xin-wei; WU Li-yu

doi:10.13422/j.cnki.syfjx.2017120145

您当前的位置：

首页 >

文章列表页 >

Cardioprotective Mechanism of Shenshao Capsule Against Myocardial Ischemia-reperfusion Injury in Rats Based on NF-B Pathway

更新时间：2024-01-04

- Cardioprotective Mechanism of Shenshao Capsule Against Myocardial Ischemia-reperfusion Injury in Rats Based on NF-B Pathway
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 12, Pages: 145-150(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017120145
  CLC： R285.5
- Published：2017
- 稿件说明：
移动端阅览
ZHAO Gui-feng, HUANG Xin-wei, WU Li-yu. Cardioprotective Mechanism of Shenshao Capsule Against Myocardial Ischemia-reperfusion Injury in Rats Based on NF-B Pathway[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(12): 145-150.
DOI：

ZHAO Gui-feng, HUANG Xin-wei, WU Li-yu. Cardioprotective Mechanism of Shenshao Capsule Against Myocardial Ischemia-reperfusion Injury in Rats Based on NF-B Pathway[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(12): 145-150. DOI： 10.13422/j.cnki.syfjx.2017120145.

摘要

目的：观察参芍胶囊及有效组分对大鼠心肌缺血再灌注损伤（MIRI）的保护作用及基于核转录因子-κB（NF-κB）炎症通路探讨其作用机制。方法：雄性Wistar大鼠，采用左冠状动脉前降支结扎30 min，再灌注120 min制备大鼠MIRI模型。随机分为7组，分别为假手术组（Sham），模型组（I/R），参芍胶囊250 mg·kg-1组（SS250），参芍胶囊500 mg·kg-1组（SS500），人参茎叶总皂苷组（TGSL），白芍浸膏粉组（Pae）及阿托伐他汀组（Ator），预灌胃7 d。2，3，5-氯化三苯基四氮唑（TTC）法测大鼠心肌梗死面积；生化法测血清肌酸激酶同工酶（CK-MB）和乳酸脱氢酶（LDH）；酶联免疫吸附测定（ELISA）法测白细胞介素（IL）-1β，肿瘤坏死因子-α（TNF-α）和IL-10含量；蛋白质免疫印迹（Western blot）测NF-κBp65，p-NF-κBp65水平。结果：与I/R组比较，SS250组，SS500组，TGSL组，Pae组及Ator组心肌梗死面积缩小（P<0.05，P<0.01）；SS250组，SS500组，TGSL组及Ator组血清CKMB及LDH水平明显下降（P<0.05，P<0.01）；SS250组，SS500组和TGSL组TNF-α含量降低（P<0.05，P<0.01）；SS250组，SS500组，Pae组和Ator组IL-1β含量明显降低（P<0.05）；SS250组，SS500组IL-10含量明显升高（P<0.05，P<0.01）；SS250组和SS500组p-NF-κBp65蛋白表达水平显著降低（P<0.01）。结论：参芍胶囊对MIRI大鼠心脏具有保护作用，抑制NF-κB炎症通路的过度激活是其作用机制之一，在抑制NF-κB表达方面参芍胶囊高剂量组优于其单一有效成分。

Abstract

Objective: To observe the cardioprotective effect of Shenshao capsule and its effective components against myocardial ischemia-reperfusion injury (MIRI) in rats and explore its action mechanism based on the nuclear factor-κB (NF-κB) pathway. Method: Male Wistar rats were used to establish MIRI models by ligation of left anterior descending coronary artery for 30 min and reperfusion for 120 min. Then these rats were randomly divided into sham operation group (Sham)

ischemia/reperfusion group (I/R)

Shenshao capsule 250 mg·kg-1 group (SS250)

Shenshao capsule 500 mg·kg-1 group (SS500)

total ginsenoside of Ginseng stems and leaves group (TGSL)

paeony group (Pae) and atorvastatin group (Ator). All of these rats received intragastric administration for 7 days. Then the myocardial infarction area was detected by triphenyltetrazolium chloride (TTC) method; the levels of serum creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) were measured by automatic biochemical analyzer. The content of interleukin-1β(IL-1β)

tumor necrosis factor-α(TNF-α) and IL-10 were determined with enzyme linked immunosorbent assay (ELISA); while Western-blot was used to detect the expression levels of NF-κBp65 and p-NF-κBp65. Result: As compared with I/R group

the myocardial infarction size was reduced in SS250

SS500

TGSL

Pae and Ator groups (P<0.05

P<0.01); CKMB and LDH levels were significantly decreased in SS250

SS500

TGSL and Ator groups (P<0.05

P<0.01). The TNF-α level was decreased in SS250

SS500 and TGSL groups (P<0.05

P<0.01); the IL-1β level was decreased in SS250

SS500

Pae and Ator groups (P<0.05); the level of IL-10 was increased in SS250 and SS500 groups (P<0.05

P<0.01); and the p-NF-κBp65 protein expression level was decreased significantly in SS250 and SS500 groups (P<0.01). Conclusion: Shenshao capsule had cardioprotective effect for MIRI rats

and the mechanism may be associated with inhibiting the over activation of NF-κB expression pathway

and the effect of Shenshao capsule high dose group was superior to its single active ingredient.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Kelong Capsules in Treatment of Benign Prostatic Hyperplasia Based on Nrf2 Pathway and Macrophage Activation

Zhenzhu Tiaozhi Capsules Reduce Renal Lipid Deposition and Inflammation in Mouse Model of Diabetic Kidney Disease via SCAP-SREBP-1c/NLRP3 Signaling Pathway

Establishment and Evaluation of Rat Model of Myocardial Ischemia-reperfusion Injury with Phlegm and Blood Stasis Blocking Collaterals Syndrome Based on Metabolomics

Mechanism of Danshenol A in Alleviating Myocardial Ischemia-reperfusion Injury-induced Ferroptosis of Cardiomyocytes

Multidimensional Analysis of Mechanisms of Nuciferine Against Cerebral Ischemia Based on Transcriptomic Data

Related Author

SONG Guanhui

FAN Danping

LI Yan

LIU Hong

PAN Jinghua

WANG Shaojun

FAN Xiang

SUN Jian

Related Institution

The First Clinical Medical College of Shaanxi University of Chinese Medicine

Experimental Research Center，China Academy of Chinese Medical Sciences

Beijing University of Chinese Medicine

Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine， Guangdong Pharmaceutical University

School of Clinical Medicine，Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰